Copenhagen, Denmark, April 28, 2026 – Zealand Pharma A/S (Nasdaq: ZEAL) (CVR-no. 20045078), a biotechnology company transforming the future of metabolic health, today announced that Boehringer ...
Share on Pinterest A new GLP-1 drug shows promise for improving metabolic health and treating obesity-related diseases like liver disease. camacho9999/Getty Images Boehringer Ingelheim, a ...
Boehringer Ingelheim’s glucagon/GLP-1 dual agonist has driven 16.6% weight loss at Week 76 of a phase 3 study. While the result fell short of the bar set by existing drugs, the German drugmaker is ...
In SYNCHRONIZE-1, participants lost up to an average of 39.2 lb (17.8 kg) from baseline after 76 weeks of treatment with survodutide, a glucagon/GLP-1 receptor dual agonist 1 The trial met both weight ...
Company announcement - No. 10 / 2026 Zealand Pharma announces Boehringer Ingelheim's novel glucagon/GLP-1 dual agonist survodutide achieved significant weight loss of 16.6% delivering meaningful metab ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results